The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

ClinicalTrials.gov ID: NCT04585750

Public ClinicalTrials.gov record NCT04585750. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 1, 2026, 1:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, tolerability and preliminary efficacy of multiple dose levels of rezatapopt as monotherapy and in Phase 1b in combination with pembrolizumab.

Study identification

NCT ID: NCT04585750
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: PMV Pharmaceuticals, Inc; Industry
Enrollment: 300 participants

Eligibility (public fields only)

Age range: 12 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 28, 2020
Primary completion: Aug 14, 2026
Completion: Dec 30, 2027
Last update posted: Aug 9, 2026

2020 – 2027

United States locations

U.S. sites: 33
U.S. states: 20
U.S. cities: 30

Facility	City	State	ZIP	Site status
University of California Irvine Chao Family Comprehensive Cancer Center	Irvine	California	92868	Withdrawn
University of San Diego Moores Cancer Center	La Jolla	California	92093	Recruiting
UCLA Jonsson Comprehensive Cancer Center	Los Angeles	California	90024	Recruiting
USC Norris Comprehensive Cancer Center	Los Angeles	California	90033	Recruiting
Rocky Mountain Cancer Center	Denver	Colorado	80218	Recruiting
Yale Cancer Center	New Haven	Connecticut	06519	Recruiting
Medical Oncology Hematology Consultants	Newark	Delaware	19713	Recruiting
University of Miami - Sylvester Comprehensive Cancer Center	Miami	Florida	33136	Recruiting
Advent Health	Orlando	Florida	32803	Recruiting
Florida Cancer Specialists South	Port Charlotte	Florida	33980	Recruiting
Massachusetts General Hospital	Boston	Massachusetts	02114	Recruiting
Dana Farber Cancer Institute	Boston	Massachusetts	02215	Recruiting
Karmanos Cancer Institute	Detroit	Michigan	48201	Recruiting
University of Nebraska Medical Center Buffet Cancer Center	Omaha	Nebraska	68105	Not yet recruiting
Columbia University Medical Center	New York	New York	10032	Not yet recruiting
Memorial Sloan Kettering	New York	New York	10065	Recruiting
Duke University	Durham	North Carolina	27705	Recruiting
The Cleveland Clinic Taussig Cancer Center	Cleveland	Ohio	44195	Recruiting
University of Oklahoma	Oklahoma City	Oklahoma	73104	Recruiting
Oregon Health & Science University (OHSU)	Portland	Oregon	97210	Recruiting
Abramson Cancer Center of the University of Pennsylvania	Philadelphia	Pennsylvania	19104	Recruiting
University of Pittsburgh Medical Center	Pittsburgh	Pennsylvania	15213	Recruiting
WellSpan York Cancer Center	York	Pennsylvania	17403	Recruiting
Medical University of South Carolina	Charleston	South Carolina	29425	Terminated
Sarah Cannon Research Institute	Nashville	Tennessee	37203	Recruiting
New Experimental Therapeutics - NEXT Oncology	Austin	Texas	78705	Recruiting
Texas Oncology	Bedford	Texas	76022	Recruiting
UT Southwest Simmons Cancer Center	Dallas	Texas	75390	Recruiting
The University of Texas MD Anderson Cancer Center	Houston	Texas	77030	Recruiting
New Experimental Therapeutics of San Antonio - NEXT Oncology	San Antonio	Texas	78229	Recruiting
Virginia Cancer Specialists	Fairfax	Virginia	22031	Recruiting
University of Washington, Fred Hutchinson Cancer Center	Seattle	Washington	98109	Recruiting
University of Wisconsin Carbone Cancer Center	Madison	Wisconsin	53705	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 44 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04585750, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 9, 2026 · Synced Sep 1, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04585750 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →